Moore Capital Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Moore Capital Management’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,666	Closed	-$10.4K	–	627
2022 Q4	$10.4K	Hold	41,666	–	–	﹤0.01%	455
2022 Q3	$4K	Hold	41,666	–	–	﹤0.01%	633
2022 Q2	$6K	Hold	41,666	–	–	﹤0.01%	672
2022 Q1	$8K	Hold	41,666	–	–	﹤0.01%	737
2021 Q4	$25K	Hold	41,666	–	–	﹤0.01%	715
2021 Q3	$24K	Hold	41,666	–	–	﹤0.01%	782
2021 Q2	$40K	Buy	+41,666	New	+$38.8K	﹤0.01%	799

Moore Capital Management's EBACW Position: Q1 2023 in Review

Moore Capital Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 41,666 shares — an estimated $10.4K sold.

Moore Capital Management first reported a position in EBACW in Q2 2021 and held it in 7 quarters. The position peaked at $40K in Q2 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Moore Capital Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Moore Capital Management sold 41,666 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $10.4K.
Moore Capital Management first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 7 quarters.
Moore Capital Management's European Biotech Acquisition Corp. Warrant position peaked at $40K in Q2 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.